Primary Tumor Cell Line (T1-A )

Unit

1×10⁶ cells / 1.0 ml

Cell Type

Tumor Cells

Tissue Type

Muscle

Organism

Mouse (M. musculus)

Donor History

Tumorigenic; obtained by subcutaneous hind quarter injection of parent cell line (GhrasT-NIH/3T3) in NIH Swiss mice and selection of cells from a hind quarter tumor.

Growth Properties

Adherent

,

fibroblast

Growth Conditions

PriCoat™ T25 Flasks (G299) or Applied Cell Extracellular Matrix (G422) are recommended for optimal cell culture. PriGrow III (TM003) + 10% FBS + 1% Penicillin/Streptomycin Solution (G255)

,

37.0°C

,

5% CO₂.  Avoid excessive alkalinity in media and renew twice weekly.

Immortalization Method

Tumor Cell Line

Full Information

https://www.abmgood.com/Primary-Tumor-Cell-Line-T1-A-t8144.html

Katalogové číslo: T8144 Kategorie: ,
Popis

This highly tumorigenic cell line is derived from a primary tumor generated by the s.c. injection of GhrasT-NIH/3T3 (Cat. T3317) cells into the hindquarters of an outbred NIH Swiss mouse. *Note: Identical injections with this T1-A cell line produced 25x more primary tumors (20 of 20 = 100% mice injected) than were produced with injections of its parental transformed GhrasT-NIH/3T3 cell line (4 of 104 = 3.8% mice injected).This cell line is part of an eight cell R/J Model of Metastatic Progression designed using the NIH Swiss mice species to acquire isogenic cell types (T4138, T8981,T3317, T8144-T8148) that capture genetic/phenotypic stages in the progression to highly metastatic growth within this same species. Compared to some other models, the metastasis related changes captured in this unique progression model are easier to discern above their less noisy isogenic background and have progressed within their native NIH Swiss in vivo micro-environments. This isogenic R/J Metastasis Cell Model was produced by an in vitro/in vitro six-step progression from mortal normal NIH Swiss mouse cells (Cat. T4138) that were used to produce immortal pre-cancer NIH/3T3 cells (Cat. T8981) that were transfected with the human HRAS oncogene to produce transformed cancer GhrasT-NIH/3T3 cells (Cat. T3317). Then beginning with a series of in vivo/in vitro progressive transfers of GhrasT-NIH/3T3 cells produced primary tumor T1-A cells (Cat. T8144) that produced local metastatic lesion T2-A cells (Cat. T8145) that simultaneously produced twin distant metastatic lung lesion T3-PA cells (Cat. T8146) with its twin distant metastatic liver lesion cells (Cat. T1847). The liver derived cells produced highly distant metastatic lung lesion cells (Cat T1848) which retained the human HRAS oncogene and they demonstrated a highly metastatic phenotype as they produced wide-spread simultaneous external and internal metastases in multiple sites in multiple mice when injected i.v. into nude NIH Swiss mice.Complete list of cells included in the R/J Model:Cat. T4138 – Normal Primary Diploid Mortal NIH Swiss Mouse Embryonic CellsCat. T8981 – NIH-3T3 CellsCat. T3317 – HRAS Stably Expressing NIH/3T3 Cell Line (GhrasT-NIH/3T3)Cat. T8144 – Primary Tumor Cell Line (T1-A )Cat. T8145 – Local Metastasis Tumor Cell Line (T2-A)Cat. T8146 – Distant Pulmonary Metastasis Tumor Cell Line (T3-PA)Cat. T8147 – Distant Hepatic Metastasis Tumor Cell Line (T3-HA)Cat. T8148 – Highly Metastatic Distant Pulmonary Tumor Cell Line (T4-PA)

O značce
Applied Biological Materials (abm) je jedním z našich klíčových dodavatelů pro biotechnologický průmysl. Společnost byla založena v roce 2004 a již více než deset let podporuje vědecké objevy v oblasti přírodních věd a vývoje léčiv. Její sídlo se nachází ve Vancouveru v Kanadě. ABM je pro nás neocenitelným partnerem zejména v  oblasti dodávek buněčných kultur, genových a virových vektorů, produktů pro molekulární biologii a PCR, nástrojů pro technologie CRISPR a RNAi, protilátek i základních reagencií pro molekulárně genetické procesy.